$1.11
6.36% yesterday
Nasdaq, Apr 03, 09:47 pm CET
ISIN
US0144421072
Symbol
ALEC
Sector
Industry

Alector, Inc. Stock price

$1.09
-0.32 22.70% 1M
-3.13 74.17% 6M
-0.80 42.33% YTD
-4.80 81.49% 1Y
-13.15 92.35% 3Y
-20.81 95.02% 5Y
-15.54 93.45% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.09 7.63%
ISIN
US0144421072
Symbol
ALEC
Sector
Industry

Key metrics

Market capitalization $108.00m
Enterprise Value $-262.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.14
EV/Sales (TTM) EV/Sales -2.61
P/S ratio (TTM) P/S ratio 1.07
P/B ratio (TTM) P/B ratio 0.85
Revenue growth (TTM) Revenue growth 3.60%
Revenue (TTM) Revenue $100.56m
EBIT (operating result TTM) EBIT $-142.79m
Free Cash Flow (TTM) Free Cash Flow $-231.16m
Cash position $413.40m
EPS (TTM) EPS $-1.24
P/E forward negative
P/S forward 10.09
EV/Sales forward negative
Short interest 7.64%
Show more

Is Alector, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Alector, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Alector, Inc. forecast:

5x Buy
63%
1x Hold
13%
2x Sell
25%

Analyst Opinions

8 Analysts have issued a Alector, Inc. forecast:

Buy
63%
Hold
13%
Sell
25%

Financial data from Alector, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
101 101
4% 4%
100%
- Direct Costs 8.84 8.84
0% 0%
9%
92 92
4% 4%
91%
- Selling and Administrative Expenses 49 49
8% 8%
48%
- Research and Development Expense 177 177
5% 5%
176%
-134 -134
6% 6%
-133%
- Depreciation and Amortization 8.84 8.84
0% 0%
9%
EBIT (Operating Income) EBIT -143 -143
6% 6%
-142%
Net Profit -119 -119
9% 9%
-118%

In millions USD.

Don't miss a Thing! We will send you all news about Alector, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alector, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role--
Neutral
Seeking Alpha
about one month ago
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference...
Neutral
GlobeNewsWire
about one month ago
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 ...
More Alector, Inc. News

Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Head office United States
CEO Arnon Rosenthal
Employees 238
Founded 2013
Website www.alector.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today